Loading...
XKRX
214450
Market cap2.34bUSD
Oct 08, Last price  
302,500.00KRW
1D
-1.94%
1Q
-5.32%
Jan 2017
648.76%
IPO
166.29%
Name

PharmaResearch Co Ltd

Chart & performance

D1W1MN
XKRX:214450 chart
P/E
19.03
P/S
5.87
EPS
15,892.83
Div yield, %
0.36%
Shrs. gr., 5y
1.79%
Rev. gr., 5y
37.56%
Revenues
535.72b
+53.01%
37,454,866,93345,953,114,75754,469,757,89164,280,682,05683,871,642,000108,745,922,000154,082,898,000194,758,644,000261,010,911,000350,115,069,000535,722,606,000
Net income
165.12b
+79.39%
12,877,827,17213,909,058,67712,955,558,10714,408,301,97416,667,485,00032,774,330,00046,688,656,00040,576,699,00076,551,214,00092,043,313,000165,120,956,000
CFO
183.46b
+32.83%
16,022,957,5838,161,008,6038,643,379,0465,203,397,41819,273,231,00032,391,669,00065,297,141,00059,403,808,00064,945,249,000138,121,879,000183,460,563,000
Dividend
Dec 29, 20251100 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults through the physical restoration; Rejuran HB plus which is used for temporary improvement of adult's crow's feet wrinkles; Rejuvenex injection, a tissue regeneration activator that regenerates connective tissues, including ligament, tendon, skin, etc.; and Rejuvenex cream, which treats the wound through rapid tissue regeneration. It also provides REJURAN, a medical device for face (especially eye, perioral area), neck, Décolleté, hands, etc; CLEVIEL prime plus and contour plus with lidocaine medical devices; D+CELL 350 TRA I; and REJURAN moisturizer for daily skin protection, as well as REJUVENEX SCULPT V; REJURAN concentrate for sensitive and aged skin; REJURAN healing eye gel and mask; REJURAN sunscreen that protects skin from UV rays; and REJURAN recover soothing mask. In addition, the company offers D+CELL 350 TRA concentrated rejuvenation cream, intensive repair serum, activating facial toner, high potency eye lift, moisture balancer, mask, hair, cream, and hydro products; REJURAN tone-up booster; REJURAN FORTE; and CONJURAN medical devices. Further, it offers functional foods; and engages in the development of software and consulting businesses. The company was formerly known as Pharma Research Products Co., Ltd. and changed its name to PharmaResearch Co., Ltd. in April 2021. PharmaResearch Co., Ltd. was founded in 1993 and is headquartered in Gangneung-si, South Korea.

Key people

Co-Chief Executive Officer, Director · since 2020
Yik Su Kim
Vice President, Director
Gi Seok Kang
Co-Chief Executive Officer, Director · since 2020
Director · since 2016
Yong Seong Kim
Non-Executive Independent Director · since 2016
Hyeon Jae Lee
Non-Executive Independent Director
Jae Hwi Lee
Non-Executive Independent Director · since 2016
IPO date
Jul 24, 2015
Employees
Domiciled in
KR
Incorporated in
KR
Headquarters & legal address
강원도 강릉시 과학단지로 77-19 (대전동)
(주) 파마리서치프로덕트
Gangneung-si, 42 25452
KR
Address
77-19, Gwahakdanji-ro, Gangneung-si, Gangwon-do
PharmaResearch Products Co., Ltd.
Gangneung-si, 42 25452
KR
Other language
PharmaResearch Products Co., Ltd.

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT